The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1/2 study to investigate the safety and efficacy of OBX-115 engineered tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced solid tumors.
 
Adam Jacob Schoenfeld
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Enara Bio; Heat Biologics; Immunocore; Iovance Biotherapeutics; Johnson & Johnson/Janssen; KSQ Therapeutics; Legend Biotech; Lyell Immunopharma; Merck; Oppenheimer; Perceptive Advisors; Prelude Therapeutics; Umoja Biopharma
Research Funding - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
Travel, Accommodations, Expenses - Instil Bio; Iovance Biotherapeutics
Other Relationship - Achilles Therapeutics; Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Harpoon therapeutics; Instil Bio; Iovance Biotherapeutics; Merck; PACT Pharma
 
Allison Betof Warner
Consulting or Advisory Role - BluePath Solutions; Bristol-Myers Squibb/Medarex; immatics; Instil Bio; Iovance Biotherapeutics; Lyell Immunopharma; Novartis; Pfizer
Research Funding - Iovance Biotherapeutics (Inst)
Travel, Accommodations, Expenses - Iovance Biotherapeutics
 
Jason Alan Chesney
Consulting or Advisory Role - Iovance Biotherapeutics; Iovance Biotherapeutics
Research Funding - Amgen; Bristol-Myers Squibb; Iovance Biotherapeutics; Replimune
Patents, Royalties, Other Intellectual Property - University of Louisville US Patents
 
Sajeve Samuel Thomas
Speakers' Bureau - Bms; Merck; Natera; Pfizer; SpringWorks Therapeutics
 
Omid Hamid
Stock and Other Ownership Interests - Bactonix
Honoraria - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Consulting or Advisory Role - Alkermes; Amgen; Bactonix; BeiGene; BioAtla; Bristol-Myers Squibb; Eisai; Genentech; Georgiamune; GigaGen; GlaxoSmithKline; Grit Biotechnology; Idera; Immunocore; Incyte; Instil Bio; IO Biotech; Iovance Biotherapeutics; Janssen; KSQ Therapeutics; Merck; Moderna Therapeutics; NGM Biopharmaceuticals; Novartis; Obsidian Therapeutics; Pfizer; Regeneron; Roche; Sanofi; Seagen; Tempus; Vial; Zelluna
Speakers' Bureau - Bristol-Myers Squibb; Immunocore; Novartis; Pfizer; Regeneron
Research Funding - Aduro Biotech (Inst); Akeso Biopharma (Inst); Amgen (Inst); Arcus Biosciences (Inst); Bioatla (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Idera (Inst); Immunocore (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Merck Serono (Inst); Moderna Therapeutics (Inst); NextCure (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Torque (Inst); Zelluna (Inst)
 
Gino Kim In
Honoraria - Array BioPharma/Pfizer; Bristol-Myers Squibb; Pfizer; regeneron; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; Castle Biosciences; Novartis; Pfizer; Replimune; Replimune; Sanofi
Speakers' Bureau - Merck; Regeneron; Rockpointe CME; Targeted Oncology
Research Funding - Bicara Therapeutics (Inst); Checkmate Pharmaceuticals (Inst); Idera (Inst); Immunocore (Inst); Instil Bio (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Obsidian Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Replimune (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Pfizer; Pfizer; Regeneron
 
Alexander Noor Shoushtari
Consulting or Advisory Role - Bristol-Myers Squibb; Erasca, Inc; Novartis
Research Funding - Alkermes (Inst); Bristol-Myers Squibb; Checkmate Pharmaceuticals (Inst); Foghorn Therapeutics (Inst); Immunocore; Iovance Biotherapeutics (Inst); Linnaeus Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Targovax (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Yazan Samhouri
No Relationships to Disclose
 
Parameswaran N Hari
Employment - Obsidian Therapeutics; Obsidian Therapeutics
Research Funding - Celgene (Inst); Millennium (Inst); Onyx (Inst); Spectrum Pharmaceuticals (Inst)
 
Giridharan Ramsingh
Employment - Gilead Sciences; Gilead Sciences; Obsidian Therapeutics; Obsidian Therapeutics; Obsidian Therapeutics
Stock and Other Ownership Interests - Genentech/Roche; Gilead Sciences; Obsidian Therapeutics
 
Camille Renard
Employment - Gilead Sciences; Obsidian Therapeutics
Stock and Other Ownership Interests - Gilead Sciences; Obsidian Therapeutics
Travel, Accommodations, Expenses - Gilead Sciences
 
Prakash Prabhakar
Employment - Obsidian Therapeutics
Stock and Other Ownership Interests - Obsidian Therapeutics
Travel, Accommodations, Expenses - Obsidian Therapeutics
 
Lauren Mclaughlin
Employment - Obsidian Therapeutics
Stock and Other Ownership Interests - Obsidian Therapeutics
Travel, Accommodations, Expenses - Obsidian Therapeutics
 
Kai He
Consulting or Advisory Role - AstraZeneca; BioNTech SE; Bristol-Myers Squibb; Iovance Biotherapeutics; Lyell Immunopharma; Mirati Therapeutics; Obsidian Therapeutics; Perthera
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Iovance Biotherapeutics (Inst); Mirati Therapeutics (Inst); Oncoc4 (Inst)